nootropic
≈ 8 min read
Names in other languages
- bgНоотропни средства
- ČeštinaNootropikum
- DeutschNootropikum
- finootropiini
- Françaisnootropique
- Españolnootrópico
- canootròpic
- Englishnootropic
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Nootropics ( ; colloquially brain supplements, smart drugs, cognitive enhancers, memory enhancers, or brain boosters) are chemical substances which purportedly improve cognitive functions, such as attention, memory, wakefulness, and self-control. In the United States, nootropics can be over-the-counter drugs and are commonly advertised with unproven claims of effectiveness for improving cognition.
The Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) have warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplements. Nootropics include both prescription drugs and dietary supplements marketed to enhance brain function, but while FDA-approved drugs have proven benefits and oversight, many dietary supplements lack evidence, may contain unapproved or hidden drugs, and pose safety and regulatory risks.
Nootropics ( ; colloquially brain supplements, smart drugs, cognitive enhancers, memory enhancers, or brain boosters) are chemical substances which purportedly improve cognitive functions, such as attention, memory, wakefulness, and self-control. In the United States, nootropics can be over-the-counter drugs and are commonly advertised with unproven claims of effectiveness for improving cognition.
The Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) have warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplements. Nootropics include both prescription drugs and dietary supplements marketed to enhance brain function, but while FDA-approved drugs have proven benefits and oversight, many dietary supplements lack evidence, may contain unapproved or hidden drugs, and pose safety and regulatory risks.
History of term
The term nootropic is derived . The first documented use of "nootropic" in reference to substances purported to increase cognitive functions was by in 1972. When researching a new compound, Giurgea found a spectrum of effects that did not align with any psychotropic drug category, leading to his proposal of a new category and the concept of the term nootropic.
Giurgea stated that nootropic drugs should have the following characteristics: They should enhance learning and memory. They should enhance the resistance of learned behaviors or memories to conditions which tend to disrupt them (e.g. electroconvulsive shock, hypoxia). They should protect the brain against various physical or chemical injuries.
They should increase the efficacy of the tonic cortical control mechanisms. They should lack the usual pharmacology of other psychotropic drugs (e.g. sedation, motor stimulation) and possess few adverse effects and low toxicity. However, there is no globally accepted or clinical definition of a nootropic.
Most compounds described as nootropic do not align with Giurgea's characteristics.
Unproven marketing claims
Nootropics include both prescription drugs and dietary supplements marketed to enhance brain function, but while FDA-approved drugs have proven benefits and oversight, many dietary supplements lack evidence, may contain unapproved or hidden drugs, and pose safety and regulatory risks. In the United States, nootropics are commonly advertised with unproven claims of effectiveness for improving cognition.
Manufacturers' marketing claims for dietary supplements are usually not formally tested and verified by independent entities. In 2019, the US FDA and FTC warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplement products.
The FDA and FTC stated that some nootropic products had not been approved as a prescription drug effective for any medical purpose, were not proven to be safe, and were illegally marketed in the United States under violation of the Federal Food, Drug, and Cosmetic Act. In 2018, in the United States, some nootropic supplements were identified as having misleading ingredients and illegal marketing.
In 2019, the FDA and FTC warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplements. From 2010 to 2019, the FDA warned numerous supplement manufacturers about the illegal status of their products as unapproved drugs with no proven safety or efficacy at the doses listed on the products, as well as misleading marketing.
Adverse effects
The main concern with pharmaceutical drugs and dietary supplements is adverse effects, including the potential for psychological dependence. Long-term safety evidence is unavailable for many nootropic compounds.
Racetams, piracetam and other compounds that are structurally related to piracetam have few serious adverse effects and low toxicity, but there is little evidence that they enhance cognition in people having no cognitive impairments. In the United States, dietary supplements may be marketed if the manufacturer can show that the supplement is generally recognized as safe, and if the manufacturer does not make any claims about using the supplement to treat or prevent any disease or condition; supplements that contain drugs or advertise health claims are illegal under US law.
Cholinergics
Some supposed nootropic substances are compounds and analogues of choline, a precursor of acetylcholine (a neurotransmitter) and phosphatidylcholine (a structural component of cell membranes). Choline bitartrate – choline bitartrate is a tartaric acid salt containing choline (41% choline by molecular weight).
One meta-analysis found choline bitartrate to be ineffective at improving any measure of cognitive performance. Citicoline – a compound consisting of choline and cytidine. A meta-analysis found that it may be effective for improving memory and learning in older people with mild cognitive decline and in people recovering from a stroke.
Racetams
Racetams, such as piracetam, oxiracetam, phenylpiracetam, and aniracetam, are often marketed as cognitive enhancers and sold over the counter. A 2019 study found that piracetam supplements sold in the United States were inaccurately labeled.
Racetams are often referred to as nootropics, but this property is not well established in humans, and nootropics are not consistently found in all racetams. The racetams have poorly understood mechanisms, although piracetam and aniracetam are known to act as positive allosteric modulators of AMPA receptors and appear to modulate cholinergic systems.
Similar compounds, such as noopept and aloracetam, do not meet the chemical definition for being a racetam, though they are considered "racetam-like" due to their high similarity. According to the FDA, Piracetam is not a vitamin, mineral, amino acid, herb or other botanical, or dietary substance for use by humans to supplement the diet by increasing the total dietary intake.
Further, piracetam is not a concentrate, metabolite, constituent, extract or combination of any such dietary ingredient. [...] Accordingly, these products are drugs, under section 201(g)(1)(C) of the Act, 21 U.S.C. § 321(g)(1)(C), because they are not foods and they are intended to affect the structure or any function of the body.
Moreover, these products are new drugs as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.
Herbs
Centella asiatica a 2017 meta-analysis showed no significant improvement in cognitive function after consuming Centella asiatica. Clinical efficacy and safety have not been scientifically confirmed for this herb.
Ginkgo biloba an extract of Ginkgo biloba leaf is marketed in dietary supplement form with claims that it can enhance cognitive function in people without known cognitive problems. However, there is no established evidence to support such effects on memory or attention in healthy people.
Panax ginseng a Cochrane review found possible "improvement of some aspects of cognitive function, behavior and quality of life" after consuming Panax ginseng but concluded that "there is a lack of convincing evidence to show a cognitive enhancing effect of Panax ginseng in healthy participants and no high quality evidence about its efficacy in patients with dementia." Bacopa monnieri a 2021 meta-analysis concluded that there is insufficient clinical evidence to support the efficacy of Bacopa monnieri in enhancing memory among healthy adults or individuals experiencing age-related cognitive decline.
Nutrients and dietary supplements
Folate no cognition-enhancing effects in middle-aged and older adults without folate deficiency have been established after the ingestion of folate. Omega-3 fatty acids DHA and EPA two Cochrane Collaboration reviews on the use of supplemental omega-3 fatty acids for ADHD and learning disorders conclude that there is limited evidence of treatment benefits for either disorder.
Two other systematic reviews found no cognition-enhancing effects in the general population. Vitamin B 12 no cognition-enhancing effects in middle-aged and older adults without B12 deficiency have been established after the ingestion of vitamin B 12 .
Vitamin B 6 no cognition-enhancing effects in middle-aged and older adults without B6 deficiency have been established after the ingestion of vitamin B 6 . Vitamin E no cognition-enhancing effects in middle-aged and older adults without vitamin E deficiency have been established after the ingestion of vitamin E.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1375030867 under CC BY-SA 4.0; modifications have been made.